PDCD1 and neoplasm: On the strength of the former theoretical result, an engineered HSV that expressed a single-chain fragment variable (scFv) against PD-1 enhanced the anti-tumor immunity [167], Zuo, S. et al. designed a VV carried with scFv targeting TIGIT [130].